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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the effectiveness of interventions that increase indoor air humidity to prevent or reduce dryness symptoms of the eyes, the
skin and the upper respiratory tract (URT) or URT infections at work and in educational settings.
B A C K G R O U N D
Following the progress of industrialisation, workplaces have in-
creasingly moved from outdoor to indoor locations. This shift has
changed the spectrum of conditions to which workers are exposed.
This fact is not only relevant to the adult working population, but
also to children and young adults, as they stay indoors for a signif-
icant part of the day throughout their education (Angelon-Gaetz
2014; Jaakkola 1991; Seppanen 2002). At most workplaces, in-
door air is a predefined condition. Its components vary consider-
ably among different occupational and educational settings. Emis-
sions from indoor sources like building materials, furnishings, of-
fice equipment and human activities result in the release of dust
as well as chemical and biological compounds. Following natural
ventilation, outdoor factors, such as pollen and particulate mat-
ters, may also contribute to indoor air quality (Alsmo 2014). In-
door air climate results from a combination of four physical pa-
rameters: temperature, radiation temperature, air velocity and hu-
midity. Humidity is defined as absolute humidity (water vapour
content of the air) whilst relative humidity (RH) is the ratio of
vapour pressure and saturation vapour pressure. RH, expressed as
a percentage, increases relative to a decrease in temperature. A hu-
midity level of 100% means that the air is completely saturated
with water vapour. The influence of different humidity levels on
pathogens, allergens and chemical factors is presented in Figure 1
(Alsmo 2014).
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Figure 1. Association of indoor relative humidity and exposure factors related to adverse health effects
(Alsmo 2014)
Description of the condition
The context of indoor air humidity and health is not a new issue
and the concept of dry air has been associated with poor air quality
since the early 20th century (Watt 1910). Currently, there is no
universal definition of dry air. It is in fact difficult to ascertain
how and to what extent human beings perceive air humidity (von
Hahn 2007), as we do not have any specific receptors to trace it
directly. As the perception of dry air is strongly affected by climatic
parameters (particularly temperature) and environmental factors
(e.g. dust), even RH levels of 50% can be experienced as dry air
under certain conditions (von Hahn 2007). Nevertheless, many
recommend avoiding conditions below a lower limit of RH of
30% to 40%, as such conditions would commonly be perceived
as uncomfortable (von Hahn 2007).
Naturally ventilated places have substantially lower levels of RH
in winter than in summer. The colder it is outside and the better
a building is naturally ventilated, the dryer indoor air becomes.
In cold seasons, building occupants increasingly complain about
dryness symptoms of the eyes, throat and skin in close temporal
relation to exposure to dry air at the workplace (von Hahn 2007).
These symptoms lack specificity and therefore it is difficult to at-
tribute them to clearly defined triggers. Furthermore, they can
emerge through various pathways and, for instance, it may remain
difficult to distinguish between symptoms due to immunological
and inflammatory mechanisms. Some of these complaints are sup-
posed to be directly associated with low levels of RH.However, the
majority of them seem to be of multifactorial origin. In addition,
they could also be the result of an indirect influence of RH due
to interactions, for example with chronic illness. Individuals with
certain pre-existing medical conditions and pre-disposed individ-
uals appear to be more affected.
Ocular symptoms like burning, itching, and sensations of dry-
ness and stinging are summarised as eye irritation (Wolkoff 2008).
These complaints occur commonly at the workplace, especially
in women (Wolkoff 2010). The prevalence of discomfort varies
considerably and ranges from 5.5% to 33.7% across studies, de-
pending on the investigated population and the diagnostic cri-
teria (Lin 2003). Overall, office workers suffer more frequently
from eye irritation than the general population (Wolkoff 2008).
A low humidity level (5% to 30%) is an environmental risk factor
that contributes to an increased prevalence of dry eyes in office
environments (Wolkoff 2008). However, there is a wide range of
individual and external risk factors associated with eye irritation
in the office environment (Wolkoff 2008). Age, medication and
hormonal changes represent personal risk factors for developing
ocular symptoms (Wolkoff 2010). Exposure to ambient irritants
such as formaldehyde and ozone can cause sensory irritation in
the eyes by trigeminal stimulation (Wolkoff 2010). The impact
of concomitant exposure to sensory irritants (e.g. volatile organic
compounds (VOCs) and ozone) and dry air on the eye has been
shown to be greater at a relative humidity level of 20% compared
to 50% (Wolkoff 2005). Furthermore, irritated eye symptoms re-
sulting from exposure to low humidity levelsmight be exacerbated
by visual display unit work (Wolkoff 2007).
The mucous membrane of the airways poses a natural barrier pro-
tecting against irritants, microbes and unfavourable climatic con-
2Humidification of indoor air for preventing or reducing dryness symptoms or upper respiratory infections in educational settings and at
the workplace (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ditions. The interaction of ciliary activity and viscosity of mu-
cosal fluid is crucial for its self-cleaning properties (Guggenbichler
2007). This mechanism is called mucociliary clearance and can be
assessed using different methods. In the airways, the air is condi-
tioned to 37°C and 100% relative humidity regardless of the am-
bient conditions (Pfluger 2013). However, despite this compen-
satory mechanism, exposure to dry air seems to induce dryness and
irritation symptoms, as has been shown in several epidemiologi-
cal studies (Ghaved 2005; Reinikainen 1991; Reinikainen 1992).
Alongside age, air humidity and hydration status there are many
other internal and external risk factors affecting mucous mem-
brane function.
Among occupants of buildings, the baseline prevalence of nasal
symptoms is often 20% (Bascom 1991). Building occupants ex-
posed to chemical and microbiological VOCs can develop symp-
toms of mucosal irritation in the eyes and upper airways by trigem-
inal stimulation, even at levels below threshold values (Wolkoff
2013). Concomitant exposure to low humidity may lead to the
instability of themucous membrane and consequently to lowering
the threshold of sensory irritation (Wolkoff 2013).
Occupants permanently exposed to lowhumidity commonly com-
plain of dry, brittle and cracked skin (Pfluger 2013). A study by
Rycroft 1980 described two outbreaks of dermatoses (pruritus,
urticarial, erythema, oedema and scaling of the skin) relating to
working environments with low RH (35%). Exposure to allergens
and irritants in the workplace or at home may also lead to dryness
or irritation symptoms of the skin and the development of der-
matitis.
A review by Arundel 1986 suggests that RH can influence the
incidence of respiratory infections. The incidence of absenteeism
or respiratory infections was found to be lower among people
working or living in environments with mid-range RH (50% to
70%) as opposed to low or high RH.
Experimental studies have shown that low humidity and low tem-
perature promote the spread of influenza virus. Therefore, the win-
ter time in temperate countries associated with exposure to cold
air outdoors and its relationship with dry air indoors may explain
the seasonality of influenza (Lowen 2014). Humidification of a
building is often coupled with airflow and ventilation, which have
been also found to influence the rate of transmission of respiratory
tract viruses (Pica 2012).
Description of the intervention
The humidity level of indoor air can be increased by:
• central or building-level interventions that increase air
humidity with air conditioning systems or whole house
humidifiers,
• local or room-level interventions, such as separate air
humidifiers that can be activated on demand, or
• other interventions, such as putting plants around the
workplace or placing a container of water or wet clothes in
proximity to a radiator or a heating system.
Technically, air humidity can be regulated with different types of
humidifiers: steam humidifiers produce vapour by thermal evap-
oration; cold atomisers atomise water with a high-frequency ven-
tilator; and the so-called ultrasound-atomisers create vapour by
ultrasound waves (Fidler 1989). Re-circulated water can be used
except for steam humidifiers. Overall, these different types of hu-
midifiers use different techniques to increase air humidity and con-
sequently, they may have different effects on health. When aim-
ing to humidify indoor air, we also need to consider the effects of
natural ventilation and seasonal variations as well as the influence
on other factors of the indoor environment.
How the intervention might work
In order to achieve the recommended level of RH indoors and
consequently to prevent dryness and irritation symptoms, work-
places and schools are being artificially humidified in some coun-
tries. There is, however, currently no clear evidence to advocate
indoor air humidification.
The use of air humidifiers is often suggested to decrease the symp-
toms of dryness and irritation attributed to heating during win-
ter, such as dry lips or eyes. This is a current opinion, but it has
not been supported by all epidemiological and laboratory studies.
Conflicting findings among studies can be explained by the use
of different clinical scores to assess the outcomes, by diverse study
populations being exposed to different ranges of RH, different
exposure assessments and different study designs (Pfluger 2013).
The variability of the study results may also be explained by the
absence (in the majority of laboratory studies) or the presence (in
studies conducted under real-life conditions) of a wide range of
different indoor air factors affecting skin and mucous membranes.
Some intervention studies have shown positive health effects of
air humidification like an increase in the percentage of patients
without dry and itchy skin (Hashiguchi 2008), alleviation of skin,
pharyngeal, nasal dryness and congestion (Reinikainen 2003), sig-
nificantly smaller dryness symptom scores for skin und mucosa
(Reinikainen 1992) and a reduction in the number and frequency
of skin und mucosa symptoms (Ghaved 2005).
Various studies, predominantly conducted under controlled lab-
oratory conditions, have evaluated the subjectively experienced
symptoms related to different humidity levels including objec-
tively-assessed signs and measurements of physiological parame-
ters. Exposure to dry air may lead to ocular dryness due to defi-
cient tear secretion and altered tear film (Lang 2014). According
to Pfluger 2013, independent studies have shown that exposure
to dry air deteriorates the quality and stability of the tear film
of the eyes. These changes consequently result in an increase of
the eye blink frequency, which is one of the objective parameters
measured in studies to assess the impact of dry air on ocular mu-
cosa (Wolkoff 2008). Furthermore, there is a clear negative rela-
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tionship between air humidity and evaporation (Pfluger 2013). A
high evaporation rate reduces the quality of the tear film. These
physiological changes concerning exposure to dry air may lead to
ocular dryness symptoms which can be alleviated by an increase
of the humidity level. Epidemiological and clinical studies suggest
that 40% RH is a favourable condition for the precorneal tear film
(Wolkoff 2008). Some studies have shown a correlation between
increasing RH and more stable pre-corneal tear film measured by
break-up time (Brasche 2005; Norbäck 2006; Wolkoff 2006). In
a study conducted by Wyon 2006, the blink frequency was signif-
icantly lower at 35% than at 5% RH. There is experimental ev-
idence that skin exposure to a low-humidity environment affects
the superficial skin layers and decreases their water content (Egawa
2002). Increasing humidity levels canmitigate skin dryness.Wyon
2006 concludes that the water content of the skin measured with
a corneometer was significantly higher at a humidity level of 35%
than 15%.
Dehydration of the respiratory mucous membrane causes an in-
crease in viscosity of the mucosal fluid and, as a consequence, cil-
iary clearance becomes less effective (Munkholm 2014). Elderly
people, especially those living in nursing homes and staying in
hospitals, seem to be more affected since they cannot regulate
their water fluid balance by themselves. A relative humidity level
below 25% leads to disadvantageous health effects in this group
(Guggenbichler 2007).
When looking at experimental evidence, studies in young popu-
lations have found that low humidity did not influence the mu-
cociliary clearance (Andersen 1972; Andersen 1974). However, a
study investigating the young as well as the elderly population has
shown impairment of mucous membrane functioning due to low
RH levels of 10% amongst the elderly when compared to younger
people (Sunwoo 2006).
According to the findings of his experimental and clinical inves-
tigations, Guggenbichler 2007 concluded that mucociliary clear-
ance seems to be more efficient when the humidity level is at least
30%. A relative humidity of 45% is even better for the self-clean-
ing function of the airways. Water mist produced by several types
of humidifiers reduces mucus viscosity (Arundel 1986).
Mucociliary clearance protects against bacterial and viral infection
(Sahin-Yilmaz 2011). If exposure to dry air results in the impair-
ment ofmucociliary clearance and leads to irritation of themucous
membrane, as a consequence, the susceptibility to infections may
be increased. This hypothesis is controversial, since only a number
of studies with objective measurements have revealed pathophys-
iological damage of mucous membranes in the upper respiratory
tract (URT) as a result of exposure to dry air. Alongside this di-
rect effect of RH, the survival and transmission capacity of some
respiratory viruses may be increased at a low level of absolute air
humidity (Koep 2013; Makinen 2009; Shaman 2010). Overall,
humidity and temperature affect host behavior (more time spent
indoors during winter time), host defences (airways mucosal func-
tion is optimal at core temperature and high humidity) (Williams
1996) and the stability and infectivity of the viruses. Furthermore,
humidity also affects the respiratory droplet size, which in turn
influences the time infectious particles remain airborne and thus,
can be inhaled.
Several, mostly older, epidemiological studies have evaluated the
effect of humidity on the incidence of respiratory infections
(Arundel 1986). The majority found a lower rate of respiratory
infections in rooms with higher humidity compared to those with
lower humidity. Most of these studies were conducted among
preschool or school children, with only two studies conducted
in adult workers. These latter two studies (Gubéran 1978; Serati
1969) found no significant differences in absenteeism due to res-
piratory tract infections between humidified and non-humidified
offices. A study has shown that an increase in absolute humidity
after humidification of the indoor environment resulted in a de-
creasing survival and transmission rate of the influenza virus (Koep
2013). At a humidity level of more than 40% the influenza virus
infectivity decayed (Tellier 2006). The surface of lipid-contain-
ing viruses is supposedly inactivated at high atmospheric humid-
ity levels (Shaman 2010). At high RH, large water-laden droplets
settle on the ground which favours removal of infectious particles
(Pica 2012).
Dryness symptoms of the eye, skin and URT, as well as fatigue and
headache, are used to describe the term ’sick building syndrome’
(SBS) (Joshi 2008; Norback 2009). These complaints seem to be
directly linked to the time spent in a particular building. Accord-
ing to Burge 2004, air conditioned buildings have generally higher
prevalence of symptomatic workers than those naturally venti-
lated. Although affected subjects perceive the sensation of dryness
in enclosed spaces, it has been shown that they are not exposed to
dry air (Burge 2004). It has been suggested that SBSmay be associ-
ated with particular volatile organic compounds present in indoor
air such as nitrogen dioxide, total volatile organic compounds and
dust (Menzres 1996). It has also been postulated that exposure to
allergens and irritants from humidifiers and conditioning systems
could cause SBS (Burge 2004). However, the exact etiology of SBS
remains unclear. Indeed, there are studies showing a positive ef-
fect of air humidification on SBS (Nordström 1994; Reinikainen
2001; Wyon 1992).
Humidifiers and air conditioning systems can be a source of mi-
crobial spread, such as bacteria, fungi and amoeba, which can be
disseminated into the air and cause health problems, such as in-
fections and allergic reactions. In particular, facilities that are not
sufficiently cleaned and maintained (Suva 2012) can be colonised
with micro-organisms. Furthermore, stagnant water in some hu-
midifiers is linked to the so-called ’humidifier lung’ (a type of hy-
persensitivity pneumonitis) and so-called ’humidifier fever’ (a type
of organic dust toxic syndrome).
In order to prevent pathogen growth, biocides are sometimes
added to the water used for humidification. These substances may
cause irritation or allergic reactions (Burge 2004).
As stated by the World Health Organization (WHO), RH of be-
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tween 60% and 90% is favourable to the growth of mould, which
is dependent on the growthmedium, themould species, the length
of time in high relative air humidity and the measure of growth
(WHO 2009).
Microbial growth as a result of high relative air humidity could
also be a cause of SBS (Norback 2009).
Furthermore, air humidity has an impact on the emission rate of
some indoor pollutants originating from building materials. This
effect may increase or decrease the presence of these chemicals,
such as formaldehyde (Haghighat 1998; Wolkoff 2007).
More recently, an increase in all-cause sick leave, which can be
considered as a distal health outcome, has also been associated
with the use of humidifiers in a manufactoring workplace (Milton
2000).
In summary, the effect of air humidity has been found to be di-
chotomised with a U-shaped association. Both low and high RH
levels above 60% are associated with respiratory symptoms, high-
lighting that adverse health outcomes may occur at both extremes
of the relative air humidity scale. Whereas the latter might result
in dryness and irritation of the mucosa and the skin (Reinikainen
2003), the former might be related to infections associated with
airborne microbial contamination (Wolkoff 2007).
See Figure 1 for an explanation of the association of indoor RH
with exposure to adverse health-related factors by Alsmo 2014.
Why it is important to do this review
In Europe, recommendations concerning indoor relative air hu-
midity differ between countries. In Switzerland, health authorities
recommend at least 30% and a maximum of 65% RH to main-
tain a comfortable room climate (SECO 2011). However, there is
no clear consensus on an optimal RH value, which may differ ac-
cording to the working environment and the symptoms addressed.
Concurrently, recommendations relating to the room temperature
should be considered, since raising temperature leads to a decrease
of RH. However, during heating periods, it is often not possible
to achieve the recommended humidity range without active hu-
midification. Further, acceptability of humidification may be of
concern, because humidified air may be perceived to be of lower
quality (Reinikainen 1997).
Here the question arises as to whether there is medical evidence
behind the recommended RH range. In this context, Figure 1
is often shown, although its evidence base remains partially un-
known. It seems questionable if it is generally possible to delineate
a threshold at which physiological impairments occur, resulting
in dryness and irritation symptoms of the skin and the mucous
membranes and consequently, that may result in URT infections.
In countries with temperate or cold climates, air humidification
is needed to reach an RH of 30% or more during the heating
season. The use of air humidifiers is associated with significant
costs, notably of electricity. However, if low humidity is associated
with adverse health outcomes, this itself would generate direct and
indirect costs, such as healthcare visits, absenteeism and reduced
productivity.
A number of literature reviews have assessed the influence of hu-
midity on human health (Alsmo 2014; Arundel 1986; Green
1979; Guggenbichler 2007; Mendell 1993; Nagda 2001; Pfluger
2013; Pica 2012; von Hahn 2007; Wolkoff 2007; Wolkoff 2008)
whilst, to date, no systematic review on this topic has been pub-
lished. Furthermore, we are not aware of any previous Cochrane
review that overlaps with this review. Consequently, there is an
urgent need to compile the available evidence about health effects
associated with air humidification amongst workers and in educa-
tional settings, respectively. Evidence has been accumulated over
the past decades and it is important to integrate evidence originat-
ing from epidemiological (field) studies. One challenge may be to
include older evidence, generated decades ago, as well as to target
different populations and settings, including children.
See Figure 2 for an explanation of the structure of our systematic
review and relevant factors for the indoor environment.
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Figure 2. Description of this Cochrane review. URT = upper respiratory tract.
O B J E C T I V E S
To evaluate the effectiveness of interventions that increase indoor
air humidity to prevent or reduce dryness symptoms of the eyes,
the skin and the upper respiratory tract (URT) or URT infections
at work and in educational settings.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include:
• cluster-randomised controlled trials (RCTs) where the
intervention is delivered at the group level, and
• quasi-randomised studies, where the method of
randomisation is not truly random, such as alternation.
Because humidification of the air is an intervention that will always
take place at a group level and is provided outside the clinical set-
ting, randomisation at the individual level is impossible. Therefore
we will also include the following non-randomised study types:
• controlled before-and-after studies, where the outcome is
measured in both the intervention and the control group twice,
once before and once after the intervention, and
• interrupted time-series studies, where outcomes are
measured at least three times before the intervention and three
times after the intervention.
Because we expect that the effect on symptoms will be quick and
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will also disappear quickly after the intervention has stopped, we
will also include randomised and non-randomised cross-over stud-
ies.
Types of participants
We will include studies conducted with:
1. Adults (18 years or older) working in any occupational
sector and in any professional activity.
2. School age children, adolescents and young adults (up to a
maximum age of 30 years) in an educational setting (e.g.
kindergarten/pre-school/nursery school, daycare centers, schools,
colleges and high schools/universities).
If only a subset of relevant participants is included in a study,
we will include this study in the review if minimal data for this
group can be extracted, including data about the intervention and
the control group. We will make it clear to the reader that the
included data are only a subset of the study. We will include both
studies that can be considered preventive because participants are
free of symptoms at the start of the study and have not requested
any intervention, and studies that can be considered remediating
because the participants complain of symptoms andhave requested
measures to improve their symptoms.
Types of interventions
We will include studies evaluating the effectiveness of any inter-
vention aiming to increase indoor air humidity. We will categorise
interventions as:
1. central interventions, i.e. at building level, air conditioning
with humidification,
2. local interventions, i.e. at room level, use of separate
humidifying devices, and
3. other interventions such as putting plants around the
workplace, etc.
We will include studies that compare the effectiveness of an air
humidifying intervention to a no intervention control group or to
an alternative intervention.
Technically, air humidity can be regulated with different types of
humidifiers: steam humidifiers produce vapour by thermal evap-
oration, cold atomisers atomise water with a high-frequency ven-
tilator and the so-called ultrasound atomisers create vapour by ul-
trasound waves (Fidler 1989).
To be included, a study has to specify absolute (AH) or relative air
humidity estimates (RH) of the intervention and the control areas
or settings. Alternatively, natural ventilation will be compared as
such, e.g. with varying levels of RH.
We will exclude studies that compare the health effects of ultra-
dry indoor spaces with uncontrolled indoor spaces, as there is no
intervention to increase air humidity.
Types of outcome measures
Primary outcomes
1. Eye symptoms. These can be self-reported eye symptoms
such as dry eyes, itching eyes or other physical symptoms of the
eye, or objectively measured outcomes such as the blinking rate.
2. Skin symptoms. These can be self-reported skin symptoms
such as a dry or itching skin or objectively measured by e.g. a
corneometer.
3. Upper respiratory tract (URT) symptoms and health
conditions related to the quality of the mucosa, such as rhinitis,
rhinosinusitis, the common cold, sore throat, hoarseness, cough,
throat inflammation or irritation, laryngitis, tonsillitis and otitis
media. We will include both self-reported and physician-
diagnosed conditions.
Secondary outcomes
1. Perceived air quality: air dryness, stuffy air, or a general
assessment of air quality.
2. Sick leave or absence from work, school or education
measured as episodes or duration.
3. Task performance, productivity and attendance.
4. Costs of the intervention to increase indoor air humidity.
5. Adverse effects.
Since effects of indoor air humidity on symptoms and infections
may be observed after very short (days) as well as longer time
periods (months), we will consider the following time scales:
• up to one month;
• between one month and three months (one season); and
• longer than three months, covering several seasons.
Exclusion criteria
This focus allows us to detect specific seasonal patterns with indoor
heating and non-heating periods that also impact and contribute
to dryness symptoms of the mucosa. Therefore, we will exclude
studies conducted in buildings situated in tropical and subtropical
climates to avoid mixed climatic patterns.
If data are reported, we will distinguish between allergic and non-
allergic symptoms and illness, and will exclude the former.
Search methods for identification of studies
Electronic searches
We will adapt the MEDLINE search strategy proposed in
Appendix 1 to the databases listed below. Sensitivity and preci-
sion of the search strategy have to be balanced. Our approach is
based on sensitivity in order to be able to identify the relevant
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information. Our search includes: a) the intervention and applica-
tion methods used, b) targeted physiological systems and related
symptoms, syndromes, infections and illness, c) effects on occu-
pational or educational attendance, and d) workplace and educa-
tional settings in general and specific ones. The study design is
not included in our search strategy as there have been different
terminologies used during the past decades. We target this aspect
within the screening process.
We will include studies published as full text, abstracts as well as
unpublished results and we will consider studies in all languages.
We will also conduct a search of unpublished trials in Clinical-
Trials.gov (www.Clinical Trials.gov) and the WHO trials portal
(www.who.int/ictrp/en/).
Wewill conduct electronic searcheswithin the followingdatabases:
Health/biomedical
• Ovid MEDLINE with available non-indexed citations
(1946 to present)
• EMBASE (1947 to present)
• CENTRAL (Cochrane Library)
• PsycINFO (1806 to present), PsycArticles, Psyndex
Occupational safety and health
• NIOSHTIC-2 (from inception to present)
• HSELINE (from inception to present)
• CISDOC (from inception to present)
• In-house database of the Division of Occupational and
Environmental Medicine, University of Zurich (this database
results from a manual search in the Current Contents Life
Sciences and the main journals of occupational and
environmental health. It includes more than 50 journals in
occupational and environmental health, internal medicine,
epidemiology, nephrology, and toxicology, and covers the period
from 1986 to December 2013)
Interdisciplinary
• Web of Science (1988 to present)
• Scopus (1960 to present)
Searching other resources
We will carefully check the reference lists of articles and reviews
for any additional eligible studies.
We will search publications from the websites of governmen-
tal agencies, such as the Centers for Disease Control - The Na-
tional Institute for Occupational Safety and Health (NIOSH),
the United States (US) Environmental Protection Agency (EPA),
American Society of Heating, Refrigerating and Air-Conditioning
Engineers (ASHRAE), Canadian Centre for Occupational Health
and Safety (CCOHS), Partnership for European Research in Oc-
cupational Safety and Health (PEROSH), and European Union
(EU) guidelines.
We will contact occupational medicine and health specialists for
additional references and grey literature. Where necessary, we will
seek missing data from authors.
Data collection and analysis
Selection of studies
After removal of duplicate studies, two review authors (KB, DI)
will independently screen titles and abstracts for inclusion. If nec-
essary for the decision process, we will read full texts. We will
resolve inconsistencies or disagreements through discussion and
by consultation with other review authors (MP, MM, HD) where
necessary. We will carefully record the process of study selection
in order to complete a PRISMA flow diagram and ’Characteris-
tics of excluded studies’ table (Liberati 2009). Data included will
cover the study design, the participants, the type and technique
of the intervention, the outcome measures and a final assessment
for inclusion. We will use Covidence for study screening and data
extraction.
Should our systematic searches identify studies conducted by au-
thors of this review, we will avoid conflict of interest by having
all decisions concerning inclusion and exclusion made by review
authors who were not involved with the study.
Data extraction and management
We will use a data collection form for study characteristics and
outcome data shown in Appendix 2 which has been piloted on
two studies in the review. Two review authors (KB,DI) will extract
study characteristics from included studies. A second author (HD
or MM) will review a random selection of data collection forms
for accuracy and completeness.
We will extract the following study characteristics:
1. General and context information: study identifier (ID),
report ID, citation, year of publication, first author, contact
author, affiliation, country, funding information, conflict of
interest (declared and if appropriate, suspected (e.g. coworker of
a relevant company)), environmental factors: season, urban or
rural, type of the building, facility type
2. Methods: aim(s) and objective(s) of the study, study design,
total study duration, study location, date of study, sample size
considerations and power calculation statistical tests used,
withdrawals, dealing with missing data
3. Participants: number of subjects included, selection
procedure, participation, representativeness, inclusion criteria,
exclusion criteria, study setting, professional activity, mean age or
age range (median, percentiles), sex/gender, sociodemographic
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characteristics (e.g. smoking status, alcohol intake,
socioeconomic level, co-morbidities, medication, atopy, family
history)
4. Interventions: types/description/content of intervention
and comparison (including type of humidification), time period
of intervention and comparison, duration of intervention and
comparison, intensity of intervention and comparison, co-
interventions, economic information. assessment of air humidity
level, control humidity level, recorded outdoor and indoor
climatic parameters (e.g. temperature)
5. Outcomes: definition/criteria and description of primary
and secondary outcomes specified and collected, and at which
time points reported or/and measured, source of outcome
criteria, person measuring/reporting, outcome measurement
(subjective: self-reported questionnaire (scales), interview
(explanation to the participants), objective: physiologic
measurements), severity of condition, diagnostic criteria if
applicable, validation of outcome tools
6. Results: humidity effects (self-reported, results of scales
and/or measured by physiological tests), adjusting for potential
confounders
Two review authors (KB, DI) will independently extract outcome
data from included studies. We will note in the ’Characteristics
of included studies’ table if outcome data were not reported in
a usable way. We will resolve disagreements by consensus or by
involving a third review author (HD, MM, MS or MP). One re-
view author (KB or DI) will transfer data into Covidence and then
transfer them to the Review Manager (RevMan 2014) file. We
will double-check that data are entered correctly by comparing the
data presented in the systematic review with the study reports. A
second review author (HD or MM) will spot-check study charac-
teristics for accuracy against the trial report. Should we decide to
include studies published in one or more languages in which our
author team is not proficient, we will arrange for a native speaker
or someone sufficiently qualified in each foreign language to fill
in the data extraction form.
Assessment of risk of bias in included studies
Following piloting to calibrate the assessments by KB, DI, HD,
MM, MP, MS, two authors (KB, DI, HD or MM) will indepen-
dently assess the risk of bias of all included studies. We will resolve
disagreements through discussion and we will consult another au-
thor (MS or MP) where necessary.
We will use the Cochrane standard ’Risk of bias’ (RoB) tool to
assess risk of bias in controlled studies. We will assess interrupted
time-series (ITS) studies with the Effective Practice and Organi-
sation of Care (EPOC) RoB Tool (EPOC 2015).
We will use the following items to assess the risk of bias in ran-
domised controlled studies:
• Sequence generation
• Allocation concealment
• Blinding of participants or organisations if applicable, and
outcome assessors
• Incomplete outcome data
• Selective outcome reporting
We have decided to use another additional item: ’control for con-
founders’.
In the case of self-reported questionnaires, blinding is not appli-
cable for the outcome assessment tool.
For ITS studies, we will base the assessment on the following areas:
• Intervention independent of other changes
• Shape of intervention pre-specified
• Interventions affect outcome data
• Allocation concealment
• Incomplete outcome data
• Selective outcome reporting
Regarding cross-over studies, we will apply suggested questions for
assessing risk of bias from theCochrane Handbook for Systematic
Reviews of Interventions (Chapter 16.4.3):
• Was use of a cross-over design appropriate?
• Is it clear that the order of receiving treatments was
randomised?
• Can it be assumed that the trial was not biased from carry-
over effects?
• Are unbiased data available?
For each of these items, we will provide one of the following sum-
mary assessments:
• Low risk of bias: plausible bias unlikely to alter the results
• Unclear risk of bias: plausible bias that raises some doubt
about the results
• High risk of bias: plausible bias that seriously weakens
confidence in the results
To judge risk of bias in randomised controlled studies as well as
in ITS, we will use the criteria proposed by EPOC 2015 as well
as criteria from the Cochrane Handbook (table 8.5.d). With re-
gard to the additional item ’control for confounders’, we will first
judge if there are important differences between groups prior to
the intervention according to confounders. If yes, we will assess
whether these relevant confounders were controlled by means of
study design (e.g. randomisation, restriction, matching) or in the
evaluation of results (e.g. stratification, statistical modelling). We
will consider the risk of bias to be low if there are any impor-
tant differences between groups or if 60% or more of the relevant
confounders were controlled in the assessed study. Otherwise we
will classify the domain as ’high risk of bias’. We will give a rating
of ’unclear risk’ if the information is insufficient or lacking. The
relevant confounders are season (outdoor air), personal character-
istics (e.g. age, gender), comorbidities, atopic conditions and co-
exposure in the workplace or in the educational setting.
We will summarise the risk of bias within and across studies for
the primary outcomes.
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We consider allocation concealment, blinding of participants and
outcome assessors and incomplete outcome data to be key do-
mains. We will judge a study to have a high risk of bias when
we judge one or more key domains to have a high risk of bias.
Conversely, we will judge a study to have a low risk of bias when
we judge low risk of bias for all key domains. We will summarise
the ’Risk of bias’ judgments across different studies for each of the
domains listed.
We will summarise and present data in a ’Risk of bias’ summary
together with a ’Risk of bias’ graph as described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Where information on risk of bias relates to unpublished data or
correspondence with the author, we will note this in the ’Risk of
bias’ table.
Assesment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse data from studies involving working populations
and from studies involving children separately.
We will report the absolute or relative indoor air humidity as
continuous variables. We will use the mean difference to assess the
intervention effect.
Predominantly, we expect to find outcome data that are dichoto-
mous, such as as percentages of participants affected. Data on
symptom severity or absence-related data are probably reported as
continuous data. In situations where data for the same outcome
are presented in some studies as dichotomous data and in other
studies as continuous data, we will calculate continuous measures
or, alternatively, we will obtain these data from investigators. As
this might not be feasible for older studies, we will present data in
three different ways: by entering the means and standard devia-
tions as continuous outcomes, by entering the counts as dichoto-
mous outcomes and by entering all of the data in text form as
‘Other data’ outcomes.
Furthermore, wewill include statistical approaches available which
will re-express odds ratios as standardised mean differences (and
vice versa), allowing dichotomous and continuous data to be
pooled together.Wewill do this as proposed in theCochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) and af-
ter consultation with a biostatistician.
Wewill enter the outcomedata for each study into the data tables in
RevMan (RevMan 2014) to calculate the intervention effects. We
will use risk ratios for dichotomous outcomes, mean differences or
standardisedmean differences for continuous outcomes, and other
types of data as reported by the authors of the studies. If only effect
estimates and their 95% confidence intervals or standard errors
are reported in studies, we will enter these data into RevMan using
the generic inverse variance method. We will ensure that higher
scores for continuous outcomes have the same meaning for the
particular outcome, explain the direction to the reader and report
where the directions were reversed if this was necessary. When the
results cannot be entered in either way, we will describe them in
the ’Characteristics of included studies’ table, or enter the data
into additional tables.
For ITS studies, we will extract data from the original papers and
re-analyse them according to the recommended methods for anal-
ysis of ITS designs for inclusion in systematic reviews (Ramsay
2003). For ITS studies, we will use the standardised change in
level and change in slope as effect measures.
Unit of analysis issues
For studies that employ a cluster-randomised design and that re-
port sufficient data to be included in the meta-analysis but do not
make an allowance for the design effect, we will calculate the de-
sign effect based on a fairly large assumed intra-cluster correlation
of 0.10. We base this assumption of 0.10 being a realistic estimate
by analogy on studies about implementation research (Campbell
2001). We will follow the methods stated in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) for the
calculations.
Dealing with missing data
Wewill contact investigators in order to verify key study character-
istics and obtain missing numerical outcome data where possible
(e.g. when a study is identified as abstract only). Where this is not
possible, and the missing data are thought to introduce serious
bias, we will explore the impact of including such studies in the
overall assessment of results by a sensitivity analysis.
If numerical outcome data, such as standard deviations or correla-
tion coefficients.aremissing, and they cannot be obtained from the
authors, we will calculate them from other available statistics such
as P values, according to the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Assessment of heterogeneity
We will assess the clinical homogeneity of the results of included
studies based on similarity of population, intervention, outcome
and follow-up.
We will consider populations as similar when they belong to the
same subgroup (working adults or children/young adults in edu-
cation).
Wewill consider interventions as similar when they include indoor
air humidification with:
1. an air conditioning system (centrally located system), or
2. local, office-based humidifiers, or
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3. other measures to increase indoor air humidity, such as for
instance putting plants around the workplace, or placing a
container of water or wet clothes in proximity to a radiator or a
heating system.
We will consider outcome measurements as similar enough to
combine when:
1. subjective symptoms are assessed (stratified by symptom
group: eye, skin, URT, combined) and when
2. objective measurements are performed (stratified by
targeted organ: eye, skin, URT, combined).
We will regard outcomes measured within the following categories
of follow-up times to be similar enough to combine:
1. up to one month,
2. between one month and three months (one season), and
3. more than three months (several seasons).
According to the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011) we will use the I² statistic to measure
heterogeneity among the trials in each analysis. If we identify sub-
stantial heterogeneity we will report it and explore possible causes
by pre-specified subgroup analysis.
Thresholds for the interpretation of I² can be misleading, since the
importance of inconsistency depends on several factors. A rough
guide to interpretation is as follows:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity*;
• 50% to 90%: may represent substantial heterogeneity*;
• 75% to 100%: considerable heterogeneity*.
(For interpreting I², Higgins 2011 suggests:
• I² = 0%; no heterogeneity,
• I² = 25%; low heterogeneity,
• I²= 50%; moderate heterogeneity,
• I² = 75%; high heterogeneity.)
*The importance of the observed value of I² depends on (i) mag-
nitude and direction of effects and (ii) strength of evidence for
heterogeneity (e.g. P value from the Chi² test, or a confidence in-
terval for I²).
In addition, we will report the 95% confidence interval of I² to
present the uncertainty in I².
Assessment of reporting biases
If we are able to pool more than five trials in any single meta-anal-
ysis, we will create and examine a funnel plot to explore possible
small study biases.
Data synthesis
When it comes to deciding how to construct comparisons and
what results to pool, we will follow the advice given by Verbeek
2012. We will analyse studies with different designs separately.
We plan to combine studies that we consider similar regarding
participants, intervention, control and study duration. We will
pool the results and analyse them statistically if appropriate.
We will pool data from studies judged to be clinically homoge-
neous usingReviewManager 5.3 software (RevMan 2014). Ifmore
than one study provide usable data in any single comparison, we
will perform meta-analysis. We will use a random-effects model
when I² is above 40%; otherwise we will use a fixed-effect model.
When I² is higher than 75% we will not pool results of studies in
meta-analysis.
For ITS, we will perform separate meta-analyses for level and slope
using the generic inverse variance method.
We will narratively describe skewed data reported as medians and
interquartile ranges.
Where multiple trial arms are reported in a single trial, we will
include only the relevant arms. If two comparisons (e.g. RH of
30% versus natural ventilation and RH of 50% versus natural
ventilation) are combined in the same meta-analysis, we will halve
the control group to avoid double-counting.
As the evidence might be too heterogeneous for statistical pooling
purposes, we will consider conducting a harvest plot, a form of ev-
idence synthesis that has been shown to be an effective way to syn-
thesise evidence for complex interventions (Ogilvie 2008; Turley
2013). Harvest plots help to synthesise evidence graphically based
on all study designs for the differential effects of humidification
across all primary and secondary outcomes.
’Summary of findings’ table
We will create ’Summary of findings’ tables using the outcomes of
eye, skin and upper respiratory tract (URT) symptoms and health
condition, measured as self- or physician-reported symptoms or
condition or as any type of specific physiological measurement.We
will use the five Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) considerations (study limi-
tations, consistency of effect, imprecision, indirectness and pub-
lication bias) to assess the quality of the body of evidence as it
relates to the studies which contribute data to the meta-analyses
for the prespecified outcomes. We will use methods and recom-
mendations described in theCochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). We will justify all decisions
to down- or up-grade the quality of studies using footnotes and we
will make comments to aid readers’ understanding of the review
where necessary.
We will analyse and report results regarding prevention or reduc-
tion (of symptoms or infections) separately.
We will present the data separately for the two subgroups, working
adults and children/young adults in education.
We will grade the evidence yielded by each comparison as one of
the following:
• High quality - further research is very unlikely to change
our confidence in the estimate of effect;
• Moderate quality - further research is likely to have an
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important impact on our confidence in the estimate of effect and
may change the estimate;
• Low quality - further research is very likely to have an
important impact on our confidence in the estimate of effect and
is likely to change the estimate;
• Very low quality - any estimate of effect is uncertain.
We will also compile an additional GRADE table showing all our
decisions about the quality of evidence and their justifications.
Subgroup analysis and investigation of heterogeneity
If we have enough included studies, we plan toundertake subgroup
analyses by professional activity (office workers compared to non-
office workers e.g. healthcare workers in hospitals), and by gender.
We will compare studies where over 50% of participants are of-
fice workers with studies where less than 50% are office workers.
Similarly we will compare studies where over 50% or participants
are female with studies where less than 50% of participants are
female. We will use the following outcomes in subgroup analyses:
1. Any effect (prevention or reduction of symptoms or
symptom score) on dryness symptoms of the mucosa (eye or
URT) or the skin;
2. Any effect (prevention or reduction of symptoms) on URT
infections or illness (e.g. rhinitis, rhinosinusitis, common cold,
sore throat, throat inflammation, laryngitis, tonsillitis, otitis
media);
3. New onset of adverse events.
Wewill use theChi² test to test for subgroup interactions inReview
Manager (RevMan 2014).
Sensitivity analysis
If there are sufficient included studies, we will perform sensitivity
analysis defined a priori to assess the robustness of our conclusions.
This will involve:
• including only studies judged to have a low risk of bias, and
• including only studies that use objective outcome
measurements.
Reaching conclusions
We will base our conclusions only on findings from the quantita-
tive or narrative synthesis of included studies for this review. We
will avoid making recommendations for practice based on more
than just the evidence, such as values and available resources. Our
implications for research will suggest priorities for future research
and outline what the remaining uncertainties are in the area.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE(R) and Ovid
OLDMEDLINE(R) 1946 to Present.
# Searches
1 Humidity/
2 humid*.ti,ab.
3 (indoor* or inside or building* or room* or plant*).ti,ab.
4 (1 or 2) and 3
5 air conditioning/ or ventilation/
15Humidification of indoor air for preventing or reducing dryness symptoms or upper respiratory infections in educational settings and at
the workplace (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
6 (air adj3 (condition* or cooling or ventilation or sparging)).ti,ab
7 ventilation.ti,ab.
8 4 or 5 or 6 or (7 and 3)
9 ((indoor and (air or environmental)) adj3 quality).mp.
10 (iaq or ieq).ti,ab.
11 or/8-10
12 Eye Diseases/ or Skin Diseases/ or Nose Diseases/ or Nasal Obstruction/ or rhinitis/ or rhinitis, atrophic/ or rhinitis, vasomotor/
or Respiration Disorders/ or Sinusitis/ or Cough/ or Hoarseness/ or Common Cold/ or Laryngitis/ or Pharyngitis/ or Tonsillitis/
or Otitis Media/ or Keratoconjunctivitis Sicca/ or Dry Eye Syndromes/
13 (dryness or irritation* or rhinitis or rhinosinusitis or Cough or Hoarseness or “common cold” or Laryngitis or Pharyngitis or
Tonsillit* or “Otitis Media” or “Keratoconjunctivitis sicca” or sneezing).ti,ab
14 Sick Building Syndrome/ or sick building syndrome.ti,ab.
15 ((nose or nasal) adj3 (disease* or symptom* or runny or running or stuffed or dry* or obstruction)).ti,ab
16 (throat adj3 (disease* or symptom* or sore or irritat* or inflam*)).ti,ab
17 (eye* adj3 (disease* or symptom* or red* or dry* or burning or irritat*)).ti,ab
18 (skin adj3 (disease* or symptom* or condition* or red* or irritat* or itch* or dry* or rash)).ti,ab
19 ((sinus or respiratory) adj3 (disease* or symptom* or condition* or health)).ti,ab
20 Absenteeism/ or Sick Leave/
21 ((sick or illness or disability) adj3 (leave* or day*)).ti,ab
22 ((absenteeism or attendance or attainment or productivity or performance) adj9 (job or work or office or school or preschool*
or “pre-school*” or kindergar#en* or daycare or “day care”)).ti,ab
23 (“mucous membrane” or mucosa or mucosal).ti,ab.
24 mucous membrane/ or exp respiratory mucosa/
25 or/12-24
26 Workplace/ or exp Schools/ or Child Day Care Centers/ or Occupational Exposure/ or Environment, Controlled/ or (office or
Work* or job or laboratory or school* or preschool* or “pre-school*” or kindergar#en* or daycare or “day care” or classroom*
or education or occupation*).ti,ab
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27 11 and 25 and 26
Appendix 2. Study screening form
I. General information
Study screening and data extraction will be performed in Covidence.
Study ID: Report ID: Data form completed:
Version number:
First author: Year of study: Data extractor:
Citation:
Publication type (specify):
Country of study: Funding source of study: Potential conflict of interest from funding?
Yes - No - Unclear
II. Study eligibility
Type of study Randomised controlled trial (RCT)
Cluster randomised controlled trial (cluster-RCT)
Interrupted time-series studies (ITS)
- clearly defined intervention point
Cross-over study
- order of intervention
Controlled before-and-after study (CBA)
- comparable control site
Quasi-randomised studies
- method of allocation
Other type of controlled studies, specify:
Does the study design meet the criteria for inclusion?
Yes
No: exclude
Unclear
Type of participants Describe the participants included:
They belong to which group:
- Adult working population
- School setting: children, young adults
Do the participants meet the criteria for inclusion?
Yes
No: exclude
Unclear
Type of interventions Is indoor air humidity assessed?
Technique:
Intervention in control group:
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(Continued)
Does the intervention meet the criteria for inclusion?
Yes
No: exclude
Unclear
Type of outcome measures List primary outcomes:
List secondary outcomes:
Does the study assess a single primary or secondary outcome, qualifying it for inclusion?
Yes
No: exclude
Unclear
III. Summary of assessment for inclusion
Include in review Exclude from review
Reason for exclusion:
Independently assessed and then compared?
Yes No
Differences resolved?
Yes No
Request further details?
Yes No
Contact detail of authors:
Notes:
Do not proceed if article is excluded from review.
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the protocol: AF, CH, HD, MM, MP, MS
Designing the protocol: AF, HD, MM, MP, MS
Coordinating the protocol: MM
Designing search strategies: M. Gosteli (specialised librarian), MM
Writing the protocol: KB, DN, MM
Providing feedback on the protocol drafts: all authors
Providing general advice on the protocol: DN, HD, MP
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